Patent Issued for Vinyl imidazole compounds as inhibitors of KRAS (USPTO 11999752).
In: Cancer Weekly, 2024-06-25, S. 1977-1977
serialPeriodical
Zugriff:
A patent has been issued to Incyte Corporation for vinyl imidazole compounds that inhibit KRAS, a protein involved in cell growth and signaling pathways. KRAS mutations are found in various cancers, including pancreatic, colorectal, and lung cancers. The patent describes the compound, its pharmaceutical composition, methods of inhibiting KRAS activity, and its potential use in therapy. This research suggests that targeting mutant KRAS could be beneficial in treating diseases characterized by KRAS mutations. [Extracted from the article]
Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Vinyl imidazole compounds as inhibitors of KRAS (USPTO 11999752).
|
---|---|
Zeitschrift: | Cancer Weekly, 2024-06-25, S. 1977-1977 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1071-7218 (print) |
Schlagwort: |
|
Sonstiges: |
|